Earnings ·
Standard BioTools reported second quarter 2026 revenue of $20.1 million, a 7.6% decline year-over-year, driven by…
LABStandard Biotools Inc.
Standard BioTools reported second quarter 2026 revenue of $20.1 million, a 7.6% decline year-over-year, driven by drops in consumables and services revenue. The company posted an operating loss of $25.4 million and a net loss from continuing operations of $21.5 million, though adjusted EBITDA improved significantly to a loss of $2.5 million from $16.1 million in the prior year period due to cost discipline and restructuring actions. Operating expenses included $14.7 million in transaction costs related to its pending merger with Treeline Biosciences. The company withdrew its full-year 2026 revenue outlook given the status of the merger, which is progressing toward a stockholder vote and anticipated closing before year-end 2026. Standard BioTools operates in the life science tools industry, providing next-generation solutions for biomedical research.